source
- Pfizer deals extend patent life for a top-selling rare disease drugSettlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have implications for others, including BridgeBio Pharma and Alnylam.BioPharma Dive · 3mo ago↗ source
- Boehringer dual-acting obesity shot hits mark in Phase 3 trialSurvodutide spurred weight loss Wall Street analysts referred to as “Wegovy-like,” and showed signs it might help preserve muscle mass as well.BioPharma Dive · 3mo ago↗ source
- STAT+: Supreme Court to hear case about ‘skinny labeling’ and generic accessThe Supreme Court Wednesday will hear oral arguments about a simmering controversy over so-called skinny labels, with implications for the availability of generics.